AD-128(AD-128) - 药物靶点：mAChRs_专利_临床

概要

基本信息

药物类型

小分子化药

别名-

靶点

mAChRs

作用机制

mAChRs拮抗剂(毒蕈碱型乙酰胆碱受体家族拮抗剂)

治疗领域

神经系统疾病呼吸系统疾病

在研适应症-

非在研适应症

阻塞性睡眠呼吸暂停综合征

原研机构

Istituto Auxologico Italiano

在研机构-

非在研机构

Istituto Auxologico Italiano

Apnimed, Inc.初创企业

最高研发阶段无进展临床2/3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与 AD-128 相关的临床试验

NCT04394143 / Completed临床2/3期IIT

Effect of AD128 on Obstructive Sleep Apnea Severity: a Randomized, Placebo-controlled, Double-blind, Cross-over Study

This study evaluates the combination of two drugs (AD128), to treat obstructive sleep apnea (OSA) severity. After a baseline evaluation and during 7 days, half of the participants will randomly receive this drug combination (AD128) and the other will receive a placebo, i.e. a drug without pharmaceutical effect. Neither the participants, nor the investigators will know in which arm participants are until the end of the study. After one week of trial, an evaluation will be perform and will be follow by one week without any treatment. During the third and last week of trial, there will be a crossover of the groups, i.e. the participants of the first group who took the two drugs (AD128) during the first week will take a placebo and those who took the placebo will take the drugs combination.

开始日期2020-10-20

申办/合作机构

Centre Hospitalier Universitaire Vaudois

[+1]

NCT04449133 / Completed临床2期IIT

Crossover, Double-blind, Phase 2 Study of AD128 Versus Placebo in Obstructive Sleep Apnea

Obstructive Sleep Apnea (OSA) is the most common and serious of the sleep disorders. Long-term, OSA is associated with increased morbidity and mortality, with a number of adverse cardiovascular, neurocognitive, metabolic, and daytime functioning consequences. No drugs are currently approved for OSA treatment.
This is a randomized, double blind, placebo controlled, cross-over, inpatient phase 2 clinical trial to examine the efficacy and the safety of a fixed dose level of AD128 in patients with OSA.

开始日期2020-07-03

申办/合作机构

Istituto Auxologico Italiano

[+2]

ACTRN12620000662965 / Completed临床2期IIT

Reboxetine and combination therapy with AD128 in sleep apnoea trial: A double-blind, 3-way cross-over study

开始日期2020-06-09

申办/合作机构

Flinders University

100 项与 AD-128 相关的临床结果

登录后查看更多信息

100 项与 AD-128 相关的转化医学

登录后查看更多信息

100 项与 AD-128 相关的专利（医药）

登录后查看更多信息

1

项与 AD-128 相关的文献（医药）

2023-01-01·Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine

The norepinephrine reuptake inhibitor reboxetine alone reduces obstructive sleep apnea severity: a double-blind, placebo-controlled, randomized crossover trial

Article

作者: Altree, Thomas J. ; Eckert, Danny J. ; Grunstein, Ronald R. ; Aishah, Atqiya ; Loffler, Kelly A.

STUDY OBJECTIVES:

Recent findings indicate that noradrenergic and muscarinic processes are crucial for pharyngeal muscle control during sleep. However, to date, reductions in obstructive sleep apnea (OSA) severity have only been detected when noradrenergic agents are combined with an antimuscarinic. Accordingly, this study aimed to determine if reboxetine alone and combined with oxybutynin reduces OSA severity. The pathophysiological mechanisms underpinning the effects of these agents were also investigated via endotyping analysis.

METHODS:

Sixteen people (6 women) with OSA completed 3 polysomnograms (∼1-week washout) according to a double-blind, placebo-controlled, three-way crossover design across 2 sites. Single doses of 4 mg reboxetine, placebo, or 4 mg reboxetine + 5 mg oxybutynin were administered before sleep (order randomized).

RESULTS:

Reboxetine reduced the apnea-hypopnea index (primary outcome) by 5.4 (95% confidence interval -10.4 to -0.3) events/h, P = .03 (-24 ± 27% in men; -0.7 ± 32% in women). Oxybutynin did not cause additional reductions in apnea-hypopnea index. Reboxetine alone reduced the 4% oxygen desaturation index by (mean ± standard deviation) 5.2 ± 7.2 events/h and reboxetine+oxybutynin by 5.1 ± 10.6 events/h vs placebo, P = .02. Nadir oxygen saturation also increased by 7 ± 11% with reboxetine and 5 ± 9% with reboxetine+oxybutynin vs placebo, P = .01. Mechanistically, reboxetine and reboxetine+oxybutynin improved pharyngeal collapsibility and respiratory control (loop gain). Larger reductions in apnea-hypopnea index with reboxetine in men were associated with higher baseline loop gain.

CONCLUSIONS:

These findings show the first evidence that reboxetine alone reduces OSA severity. The data provide novel insight into the role of norepinephrine reuptake inhibitors on upper airway stability during sleep and are important to inform future pharmacotherapy development for OSA.

CLINICAL TRIAL REGISTRATION:

Registry: Australian New Zealand Clinical Trials Registry; Name: Reboxetine and Combination Therapy with AD128 in Sleep Apnoea Trial: A Double-Blind, 3-Way Cross-Over Study; URL: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=374614&isReview=true; Identifier: ACTRN12620000662965.

CITATION:

Altree TJ, Aishah A, Loffler KA, Grunstein RR, Eckert DJ. The norepinephrine reuptake inhibitor reboxetine alone reduces obstructive sleep apnea severity: a double-blind, placebo-controlled, randomized crossover trial. J Clin Sleep Med. 2023;19(1):85-96.

100 项与 AD-128 相关的药物交易

登录后查看更多信息